Get access

The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD

Authors

  • H. E. Seaman BSc,

    Corresponding author
    1. Department of Pharmacoepidemiology, Postgraduate Medical School (E5), University of Surrey, Guildford, UK
    • Department of Pharmacoepidemiology, Postgraduate Medical School (E5), University of Surrey, Stirling House, The Surrey Research Park, Guildford, GU2 7DJ, UK.
    Search for more papers by this author
  • C. S. de Vries MSc Pharm, PhD,

    1. Department of Pharmacoepidemiology, Postgraduate Medical School (E5), University of Surrey, Guildford, UK
    Search for more papers by this author
  • R. D. T. Farmer MB, PhD, FFPHM, MFPM

    1. Department of Pharmacoepidemiology, Postgraduate Medical School (E5), University of Surrey, Guildford, UK
    Search for more papers by this author

Abstract

Purpose

To explore the risk of liver disorders associated with cyproterone acetate combined with ethinyloestradiol (CPA/EE). CPA/EE is licensed in the UK for the treatment of women with acne and hirsutism and is a treatment option for polycystic ovary syndrome (PCOS). It acts as a contraceptive also.

Methods

Using the General Practice Research Database, we conducted a cohort analysis and case-control study in women aged 15–39 with acne, hirsutism or PCOS to estimate the risk of liver disorders associated with CPA/EE.

Results

Compared with cases exposed to conventional combined oral contraceptives (COCs), the age-adjusted incidence rate ratio for liver disorders in women using CPA/EE was 1.7 (95%CI: 0.9,3.4) and compared with no use it was 1.5 (95%CI: 0.8, 2.8). In the case-control study, the adjusted odds ratio (OR) for liver disorders in women exposed to CPA/EE was 1.6 (95%CI: 0.7, 3.5) and 0.8 (95%CI: 0.5, 1.3) for exposure to conventional COCs, compared with no use. The risk of liver disorders in women prescribed CPA/EE was not significantly greater than that in women prescribed conventional COCs (OR: 2.1 [95%CI: 0.9, 4.8]).

Conclusion

Our results do not indicate an increased risk for liver disorders associated with CPA/EE use in women with acne, hirsutism or PCOS after adjusting for potential confounding. This may be due to lack of statistical power. Copyright © 2003 John Wiley & Sons, Ltd.

Ancillary